MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41409-021-01555-9

Медицинская библиотека · Bone marrow transplantation · 2022

Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP.

Onida Francesco, Sbianchi Giulia, Radujkovic Aleksandar, Sockel Katja, Kröger Nicolaus, Sierra Jorge, Socié Gerard, Cornelissen Jan, Poiré Xavier, Raida Luděk, Bourhis Jean Henri, Finke Jürgen, Passweg Jakob, Salmenniemi Urpu, Schouten Harry C, Beguin Yves, Martin Sonja, Deconinck Eric, Ganser Arnold, Zver Samo, Lioure Bruno, Rohini Radia, Koster Linda, Hayden Patrick, Iacobelli Simona, Robin Marie, Yakoub-Agha Ibrahim

СтатьяПеревод в очереди

Аннотация

Recently a new three-group clinical classification was reported by an International Consortium to stratify CMML patients with regard to prognosis. The groups were defined as follows: (1) Myelodysplastic (MD)-CMML: WBC ≤ 10 × 109/l, circulating immature myeloid cells (IMC) = 0, no splenomegaly; (2) MD/MP (overlap)-CMML: WBC 10-20 × 109/l or WBC ≤ 10 × 109/l but IMC > 0 and/or splenomegaly; (3) Myeloproliferative (MP)-CMML: WBC > 20 × 109/l. By analysing EBMT Registry patients who underwent allo-HCT for CMML between 1997 and 2016, we aimed to determine the impact of this classification on transplantation outcome and to make a comparison with the conventional WHO classification (CMML-0/CMML-1/CMML-2). Patient grouping was based on the data registered at time of transplantation, with IMC replaced by peripheral blasts. Among 151 patients included in the analysis, 38% were classified as MD-CMML, 42% as MD/MP-CMML and 20% as MP-CMML. With a median survival of 17 months in the whole series, MD-CMML patients were distinguished as a low-risk group with higher CR rate at transplant and a longer post-transplant 2-year progression-free survival in comparison to others (44.5% vs 33.5%, respectively), whereas the WHO classification was superior in identifying high-risk patients (CMML-2) with inferior survival outcomes.

Для цитирования: Onida Francesco, Sbianchi Giulia, Radujkovic Aleksandar, Sockel Katja, Kröger Nicolaus, Sierra Jorge, Socié Gerard, Cornelissen Jan, Poiré Xavier, Raida Luděk, Bourhis Jean Henri, Finke Jürgen, Passweg Jakob, Salmenniemi Urpu, Schouten Harry C, Beguin Yves, Martin Sonja, Deconinck Eric, Ganser Arnold, Zver Samo, Lioure Bruno, Rohini Radia, Koster Linda, Hayden Patrick, Iacobelli Simona, Robin Marie, Yakoub-Agha Ibrahim. Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP.. Bone marrow transplantation. 2022. DOI: 10.1038/s41409-021-01555-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.